Eli Lilly and Company is back with even more positive data on orforglipron, its oral GLP-1 receptor agonist. The company says it is "moving with urgency" toward gaining key regulatory approvals and getting the drug in the hands of patients. Eli Lilly and Company is back with even more positive data on orforglipron, its oral GLP-1 receptor agonist. The company says it is "moving with urgency" toward gaining key regulatory approvals and getting the drug in the hands of patients. | | |
|
Prem Soman, MD, PhD, explained how early detection and new therapies have been game-changers for the treatment and diagnosis of cardiac amyloidosis. Prem Soman, MD, PhD, explained how early detection and new therapies have been game-changers for the treatment and diagnosis of cardiac amyloidosis. | | |
|
"Today’s sentence sends a deterrent message to doctors and the healthcare industry," according to a DOJ statement. "If you abuse patient trust for profit, you will face justice." "Today’s sentence sends a deterrent message to doctors and the healthcare industry," according to a DOJ statement. "If you abuse patient trust for profit, you will face justice." | | |
|
|
When Taylor Swift speaks, the world listens. And when she recently appeared on a podcast for the very first time, she shared the story of how a nuclear stress test saved her father's life. When Taylor Swift speaks, the world listens. And when she recently appeared on a podcast for the very first time, she shared the story of how a nuclear stress test saved her father's life. | | |
|
The Class I recall includes more than 26,000 vascular stents from Boston Scientific. These devices have been linked to a risk of potential resistance when the stent delivery system is being withdrawn. The Class I recall includes more than 26,000 vascular stents from Boston Scientific. These devices have been linked to a risk of potential resistance when the stent delivery system is being withdrawn. | | |
|
"We're constantly trying to keep our fingers on the pulse of what's happening in the real world," explained Joan Michaels, RN, director of the STS/ACC TVT Registry. "This is not a trial; this is real-world experience." "We're constantly trying to keep our fingers on the pulse of what's happening in the real world," explained Joan Michaels, RN, director of the STS/ACC TVT Registry. "This is not a trial; this is real-world experience." | | |
|
It's another big victory for Abbott's bioresorbable stent for BTK PAD. It's another big victory for Abbott's bioresorbable stent for BTK PAD. | | |
|
|
Competition was once fierce between interventional cardiologists and cardiac surgeons, but that has changed over the years. "It is absolutely a partnership," one veteran surgeon told Cardiovascular Business. Competition was once fierce between interventional cardiologists and cardiac surgeons, but that has changed over the years. "It is absolutely a partnership," one veteran surgeon told Cardiovascular Business. | | |
|
A new two-year study is focused on the potential of using commercially available fitness trackers to identify patients who may face an increased risk of CVD. A new two-year study is focused on the potential of using commercially available fitness trackers to identify patients who may face an increased risk of CVD. | | |
|
This is a rapidly growing area of interest in cardiology as research continues to find close links between heart disease and kidney disease. This is a rapidly growing area of interest in cardiology as research continues to find close links between heart disease and kidney disease. | | |
|
|
FDA clears AI-powered glucose monitoring app. The clearance marks a first for an over-the-counter tool in this category. FDA clears AI-powered glucose monitoring app. The clearance marks a first for an over-the-counter tool in this category. | | |
|
FDA 510(k) clearance does not require that AI devices are subject to prospective human studies prior to approval. FDA 510(k) clearance does not require that AI devices are subject to prospective human studies prior to approval. | | |
|
